Wilkins Investment Counsel Inc. Boosts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wilkins Investment Counsel Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 630.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 54,657 shares of the medical research company’s stock after buying an additional 47,172 shares during the period. IQVIA comprises approximately 1.6% of Wilkins Investment Counsel Inc.’s portfolio, making the stock its 28th biggest holding. Wilkins Investment Counsel Inc.’s holdings in IQVIA were worth $10,741,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in IQV. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in shares of IQVIA by 353.7% during the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 191 shares in the last quarter. Versant Capital Management Inc increased its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA in the 4th quarter worth $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.9 %

Shares of IQV stock opened at $186.80 on Thursday. The company’s 50-day moving average price is $195.71 and its 200-day moving average price is $209.36. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $32.93 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.29.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on IQV shares. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.